<DOC>
	<DOCNO>NCT02049736</DOCNO>
	<brief_summary>Chronic kidney disease ( CKD ) chronic viral hepatitis due hepatitis B virus ( HBV ) major public health problem . Treatment chronic HBV infection CKD patient , however , well defined insufficient data clinical trial . Telbivudine new antiviral provide effective sustained viral suppression patient compensate chronic hepatitis B infection . Unlike nucleotide nucleoside analogue , renal toxicity uncommon telbivudine , dosage adjustment require patient mild renal impairment . We propose conduct open-label single-arm study evaluate effect telbivudine renal function proteinuria patient chronic HBV infection mild-to-moderate renal impairment . Twenty patient chronic HBV infection chronic kidney disease ( estimate glomerular filtration rate 15 60 ml/min ) recruit . They treat telbivudine , dosage adjust accord thei renal function , 5 year . Serum HBV DNA , proteinuria , renal function , urinary inflammatory marker monitor .</brief_summary>
	<brief_title>Effect Telbivudine Renal Function Proteinuria Patients With CHB &amp; Chronic Renal Diseases</brief_title>
	<detailed_description>Chronic kidney disease ( CKD ) major public health problem worldwide past decade , partly increase prevalence hypertension , diabetes mellitus , elderly individual country . In southeast Asia , chronic viral hepatitis due hepatitis B virus ( HBV ) also pose significant morbidity mortality [ 2 ] . Chronic HBV infection cause chronic glomerulonephritis CKD . More importantly , patient CKD , irrespective underlying renal diagnosis , acquire HBV infection high morbidity mortality rate , management chronic HBV infection among CKD patient antiviral agent associate high risk adverse effect . The optimal management CKD associate chronic HBV infection well defined insufficient data clinical trial . Telbivudine ( Sebivo® ; Tyzeka® ) synthetic nucleoside analogue inhibits replication HBV . Telbivudine potent antiviral provide effective sustained viral suppression patient compensate chronic hepatitis B infection , use treatment adult chronic hepatitis B evidence viral replication persistently elevate serum transaminase level , histological evidence active disease . Unlike nucleoside nucleotide analogue , renal toxicity telbivudine uncommon , dose adjustment necessary patient moderate severe renal impairment . Recent data suggest telbivudine treatment may beneficial effect renal function .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>age 1870 year hepatitis B surface antigen ( HBsAg ) positive clinical indication antiviral therapy accord Asian Pacific guideline [ 16 ] HBeAg positive , ALT &gt; 2 time upper limit normal AND HBV DNA &gt; 20,000 IU/ml AND HBV DNA &lt; 9 log10 copies/mL ; OR HBeAg negative , ALT &gt; 2 time upper limit normal AND HBV DNA &gt; 2,000 IU/ml AND HBV DNA &lt; 7 log10 copies/mL ; OR Evidence advance liver fibrosis liver cirrhosis AND detectable HBV DNA estimate glomerular filtration rate ( GFR ) 15 60 ml/min/1.73m2 willingness give write consent comply study protocol Pregnancy , lactate childbearing potential without effective method birth control Severe gastrointestinal disorder interfere ability receive absorb oral medication History malignancy , include leukemia lymphoma within past 2 year Active systemic infection . Any severe coexisting disease , limited , advanced liver cirrhosis , myocardial infarction , cerebrovascular accident , malignant hypertension History drug alcohol abuse within past 2 year Patients receive antiviral therapy chronic hepatitis B within past 12 month Patients receive treatment corticosteroid immunosuppressive / cytotoxic agent On investigational drug within last 3 month History psychological illness condition interfere patient 's ability understand requirement study History noncompliance Known history sensitivity allergy telbivudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>